Shionogi redasemtide (S-005151) in the treatment of acute ischemic stroke (AIS) Phase 2 clinical success!

Japanese pharmaceutical company Shionogi recently announced the positive results of a Phase 2 clinical trial of the regeneration-inducing drug S-005151 (redasemtide) in patients with acute ischemic stroke (AIS). Redasemtide is a regeneration-inducing drug in development that regenerates tissue damaged by injury or disease by using a drug instead of living cells.

Qhov no yog ib qho randomized, ob-dig muag, tshuaj placebo-tswj tshuaj nyob rau hauv cov neeg mob 4.5 mus rau 24 teev tom qab pib ntawm AIS uas tsis yog cov neeg sib tw rau kev kho mob revascularization (thrombolysis lossis mechanical thrombectomy [MT]). Lub hom phiaj tseem ceeb ntawm kev sim yog los tshuaj xyuas qhov ua tau zoo thiab kev nyab xeeb ntawm redasemtide. Thawj qhov kawg yog qhov ua tau zoo raws li kev soj ntsuam los ntawm Modified Rankin Scale (mRS) 90 hnub tom qab kho. Modified Rankin Scale yog ib qho kev ntsuas uas feem ntau siv los ntsuas kev tsis taus lossis kev vam khom hauv cov haujlwm niaj hnub hauv cov neeg mob stroke lossis lwm yam neuropathy.

Cov txiaj ntsig tau pom tias qhov kev sim tau ntsib nws qhov kawg ntawm qhov kawg. Hauv qhov kev sim no, qhov tshwm sim ntawm cov xwm txheej tsis zoo yog qhov zoo sib xws ntawm cov pab pawg redasemtide thiab cov placebo, lees paub tias redasemtide tau txais txiaj ntsig zoo.

Raws li cov txiaj ntsig tau zoo ntawm qhov tau hais los saum toj no Theem 2 kev sim tshuaj, Shionogi yuav npaj rau kev hloov pauv ntawm redasemtide mus rau lub ntiaj teb Phase 3 kev sim tshuaj rau kev kho mob stroke (AIS).

redasemtide belongs rau cov chav kawm tshiab tshiab ntawm cov tshuaj hu ua" Regeneration-inducing Medicine" uas ua rau cov ntaub so ntswg puas vim raug mob los yog kab mob los ntawm kev ua kom lub cev ntau tshaj' lub peev xwm los kho cov ntaub so ntswg thiab kev ua haujlwm ntawm lub cev. Redasemtide ua rau kom rov tsim kho cov ntaub so ntswg puas los ntawm kev tsim cov pob txha pob txha-los ntawm mesenchymal qia hlwb mus rau hauv cov ntshav peripheral, ua rau cov kab mob mesenchymal hauv cov ntshav ncig thiab tsub zuj zuj hauv cov ntaub so ntswg puas.

Tam sim no, Shionogi tab tom txhim kho kev txhim kho redasemtide hauv dystrophic epidermolysis bullosa, kab mob siab ntev, mob hauv caug osteoarthritis, cardiomyopathy, thiab mob stroke ischemic stroke (AIS). Redasemtide yav dhau los tau ua kom pom qhov ua tau zoo hauv dystrophic epidermolysis bullosa (DEB) hauv Phase 2 kev tshawb fawb soj ntsuam ntawm Osaka University thiab lwm lub tsev haujlwm.